Tyra Biosciences

TYRAPhase 2

Founded 2018tyra.bio

Tyra Biosciences is focused on advancing a robust pipeline of selective FGFR inhibitors for oncology and genetically defined conditions. Its core technology platform enables rapid structure-based design to create molecules that address key limitations of current therapies, such as resistance mutations and off-target toxicity. With multiple clinical-stage assets, including dabogratinib in Phase 2 and TYRA-200/430 in Phase 1, the company is targeting significant markets in achondroplasia, bladder cancer, and cholangiocarcinoma.

Market Cap

$2.0B

Founded

2018

Focus

Small Molecules

TYRA · Stock Price

USD 37.15+25.59 (+221.37%)

Historical price data

AI Company Overview

Technology Platform

A rapid structure-based drug design platform leveraging hundreds of internally solved FGFR co-crystal structures to create next-generation, selective kinase inhibitors aimed at overcoming resistance mutations and minimizing off-target toxicity.

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.5...	Achondroplasia	Phase 2
Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA...	Low Grade Upper Tract Urothelial Carcinoma	Phase 2
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD	Low-grade NMIBC	Phase 2
TYRA-300	Locally Advanced Urothelial Carcinoma	Phase 1/2
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cy...	Locally Advanced Cholangiocarcinoma	Phase 1

Funding History

Total raised: $280M

IPO$150MUndisclosedSep 23, 2021

Series B$80MRA Capital ManagementJun 15, 2021

Series A$50MAlta PartnersJan 15, 2020

Opportunities

Tyra has significant growth opportunities in large, validated markets: establishing dabogratinib as a superior oral therapy for achondroplasia versus the current standard of care (injectable), capturing share in FGFR3-mutant urologic cancers where resistance is a problem, and expanding into FGFR2-driven cholangiocarcinoma and FGFR4-driven HCC with its next-generation candidates.

Risk Factors

Key risks include clinical trial failures, intense competition from approved and investigational FGFR inhibitors, potential safety issues emerging in larger trials, regulatory hurdles, and the ongoing need to raise capital in volatile public markets, which could lead to shareholder dilution.

Competitive Landscape

Tyra competes with approved pan-FGFR inhibitors (erdafitinib, pemigatinib, futibatinib) and achondroplasia therapies (vosoritide). Its main differentiation is its structure-based design of selective inhibitors aimed at overcoming the resistance mutations and dose-limiting toxicities that limit current therapies, positioning its candidates as potential best-in-class agents.

Publications

Patents

Pipeline